Drugs / LG-0317
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07708428 | Jul → Sep 2026 overdue | — | LinGang Laboratory | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07522970 | Apr → Sep 2026 overdue | — | LinGang Laboratory | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LG-0317 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07522970 ↗ |
| Route | Oral | “single oral dose of LG-0317 tablet” NCT07522970 ↗ |